41. **Finelli PF**. Primary CNS lymphoma in myasthenic on long-term azathioprine. J Neurooncol 2005; 74:91–92.
42. **Sanders DB, Hart IK, Mantegazza R,, et al**. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71:400–406.
43. **Muscle Study Group**. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394–399.
44. **Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al**. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61:1438–1440.
45. **Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB**. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41:593–598.
46. **Merlob P, Stahl B, Klinger G**. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol 2009; 28:105–108.
47. **Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G**. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316:719–724.
48. **Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M**. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11:97.
49. **Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group**. Phase II trial of methotrexate in myasthenia gravis. Ann N Y Acad Sci 2012; 1275:23–28.
50. **Díaz-Manera J, Martínez-Hernández E, Querol L, et al**. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78:189–193.
51. **Gronseth GS, Barohn RJ**. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7–15.
52. **Kumar V, Kaminski HJ**. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011; 11:89–96.
53. **Pompeo E, Tacconi F, Massa R, Mineo D, Nahmias S, Mineo TC**. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg 2009; 36:164–169.

***ADDRESS**: Yuebing Li, MD, PhD, Department of Neurology, Neuromuscular Center, Neurological Institute, S90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: Liy@ccf.org*

CORRECTION

Paget disease of bone

(JULY 2013)

In the article "Paget disease of bone: Diagnosis and drug therapy" in the July 2013 issue, an error occurred on page 458, under the subheading "Intravenous bisphosphonates." The text read, "Pamidronate was approved in 1994. Although it does not contain nitrogen, it is quite effective in many patients with Paget disease." Pamidronate in fact does contain nitrogen.